Navigation Links
Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Date:11/18/2011

TARRYTOWN, N.Y., Nov. 18, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks (2 months).

The approval of EYLEA was granted under a Priority Review, a designation that is given to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists.  This approval was based upon the results of two Phase 3 clinical studies.  In these studies, EYLEA dosed every eight weeks, following three initial monthly injections, was clinically equivalent to the standard of care, Lucentis® (ranibizumab injection) dosed every four weeks, as measured by the primary endpoint of maintenance of visual acuity (less than 15 letters of vision loss on an eye chart) over 52 weeks.  The most common adverse reactions (frequency of 5% or more) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and increased intraocular pressure.  The adverse event profile was similar to that seen with ranibizumab.

"The approval of EYLEA offers a much needed new treatment option for patients with wet AMD," said Jeffrey Heier, M.D., a clinical ophthalmologist and retinal specialist at Ophthalmic Consultants of Boston, Assistant Professor of Ophthalmology at Tufts School of Medicine, and Chair of the Steering Committee for the VIEW 1 trial.
"EYLEA offers the potential of achieving the efficacy we've come to expect from current anti-VEGF agents, but with less frequent injections and no monitoring requirements.  This may reduce the need for cos
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
2. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
3. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
4. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
5. Regeneron Reports Second Quarter 2011 Financial and Operating Results
6. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
7. Trading in Regeneron Common Stock Halted
8. Regeneron Reports First Quarter 2011 Financial and Operating Results
9. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
10. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
11. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... NiQ Health, "the leader ... high level interface capabilities of their CarePlus™ nurse ... The partnership between CarePlus™ and ClinicAll integrates ... patients to choose the most appropriate alarm and ... advanced functionality of CarePlus™ allows patient alarms to ...
(Date:3/30/2015)... , March 30, 2015 DURECT ... it has initiated a multi-dose Phase 1 clinical ... lead molecule in DURECT,s Epigenomic Regulator Program.  DUR-928 ... that may have broad applicability in metabolic diseases ... nonalcoholic steatohepatitis (NASH).  It may also play an ...
(Date:3/30/2015)... Calif. , March 30, 2015  BioPharmX ... on the development of novel drug delivery products ... underserved markets, today announced the appointment of ... retail industry veteran, to its board of directors.  ... it continues to expand its national roll-out of ...
Breaking Medicine Technology:NiQ Health Announces CarePlus(TM) Integration with ClinicAll 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 4BioPharmX Corporation Appoints Stephen Morlock To Its Board Of Directors 2BioPharmX Corporation Appoints Stephen Morlock To Its Board Of Directors 3
... Calif., Sept. 13 QuantaLife, a new life science ... received an NIH grant totaling $6 million over 5 ... detecting methicillin-resistant Staphylococcus aureus (MRSA) infections. The grant, from ... part of the National Institutes of Health, will fund ...
... 13 Pharmacyclics, Inc. (Nasdaq: PCYC ) today reported ... June 30, 2010.   During the fiscal year ended ... No revenue was generated in the fiscal year ended June 30, ... June 30, 2010 was $15.0 million, or $0.31 per share. This ...
Cached Medicine Technology:Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 2Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 3Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 4Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 5Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 6Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 7Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 8Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 9Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 10Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 11Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 12Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 13Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 14
(Date:3/30/2015)... (PRWEB) March 30, 2015 The pharmaceutical ... and flexible biological manufacturing plants. This is primarily due ... business. , This has forced facilities to produce and ... The existing facilities have been forced to expand production, ... change of ownership. , Most of these facilities have ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 GoHooper.com announces ... three locations providing medical care to infants, children and ... for their children. , The owner/provider Mark Hughes, ... Grace Pediatrics, strive to provide expertise in the extensive ... Patients receive care from health professionals who meet the ...
(Date:3/30/2015)... Dr. Jeffrey Allred DDS, with his practice based ... second opinion consultations for patients who need a second ... second opinions show how small percentage of dentistry patients go ... 6%” – says Dr. Allred. , “People should not ... the dental care provider, for the simple fact that every ...
(Date:3/30/2015)... Southern Med Law, a law firm representing victims ... a Mirena IUD lawsuit on behalf of ... birth in 2012. The complaint, which is currently pending ... IUD failed to prevent pregnancy due to problems locating ... remove. The inability to remove the IUD from her ...
(Date:3/30/2015)... 2015 “ iCareTech ” was featured on ... a look at the latest and coolest technology products and ... and technology expert, conducted the review and shared with viewers ... to the medical and health fields. , Wearable technology has ... the past couple of years. Well, at CES, NewsWatch TV ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: Aging Aseptic and Biological Manufacturing Facilities: Design and Renovation for Compliance Webinar, April 16, 2015 2Health News:FDAnews Announces: Aging Aseptic and Biological Manufacturing Facilities: Design and Renovation for Compliance Webinar, April 16, 2015 3Health News:Nashville Web Design Company Announces New Site Launch For Pediatrics Doctor 2Health News:Allred Dental Offers Complimentary 15 Minute Consults with Dr. Jeffrey Allred in San Marcos, CA 2Health News:Mirena Lawsuit Filed By Southern Med Law Seeks Compensation For Purported Wrongful Death Following Premature Birth Of Infant 2Health News:Mirena Lawsuit Filed By Southern Med Law Seeks Compensation For Purported Wrongful Death Following Premature Birth Of Infant 3Health News:Mirena Lawsuit Filed By Southern Med Law Seeks Compensation For Purported Wrongful Death Following Premature Birth Of Infant 4Health News:World’s First Medical Intelligent Band was Featured on NewsWatch Television on January 30, 2015 2
... of a particular drug than the individual effect of both the ... where the avian bird flu is posing a serious threat across ... is a prescribed drug for seasonal flu, because it will be ... in Asia and reported in other areas mutates into a human ...
... have been implicated in a number of human ... pox, measles, rubella, polio, hepatitis, warts, influenza, common ... have now //,reported that a potentially life threatening ... population. ,The findings...indicate the possible presence ...
... Carskadon from Bradley Hospital Sleep Laboratory, Brown University has found ... to bed late. Study has found that teens are not ... they get up early in the morning resulting in a ... in the Journal American Academy of Sleep Medicine. ...
... US and University of Tokyo, Japan have found a faster ... a bird flu outbreak involving mutant strain of virus occurs. ... the avian virus which may be very lethal and may ... University of Wisconsin-Madison, working with Japanese colleagues from the University ...
... more likely to occur in patients who take high ... safety profile of non-steroidal anti-inflammatory drugs (NSAIDs). // Furthermore, ... days after starting an ibuprofen regimen. ... favorable safety profiles of all of the traditional non-selective ...
... of India has today assured that there was no real ... // ,The government has set up a nationwide ... the domestic poultry population and migratory birds and to constantly ... as and when required. ,"We are keeping a ...
Cached Medicine News:Health News:Tamiflu Shortage Can Be Better Handled By Combining It With Probenecid 2Health News:Reports of Hantavirus infection in India raise concerns 2Health News:Faster way of producing Bird flu vaccine using Reverse Genetics 2
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
... Aerosol barrier tips eliminate false signals ... designed and tested, Promega Barrier Tips ... with amplified nucleic acids (PCR(a)), radioactive ... forensic and serological specimens. , ,Promega ...
... AvantGard Low Binding 20l Barrier Tips. Low ... DNA and proteins bound to the tip. Most ... which means the focus is on liquid not ... focuses on low binding which reduces the binding ...
... eliminate false signals and contamination caused ... Promega Barrier Tips offer performance and ... acids (PCR(a)), radioactive isotopes, tissue culture ... specimens. , ,Promega Barrier Tips are ...
Medicine Products: